These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 11124095

  • 1. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
    Mischke R, Grebe S.
    Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
    [Abstract] [Full Text] [Related]

  • 2. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R, Jacobs C.
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [Abstract] [Full Text] [Related]

  • 3. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
    Scheuch G, Brand P, Meyer T, Herpich C, Müllinger B, Brom J, Weidinger G, Kohlhäufl M, Häussinger K, Spannagl M, Schramm W, Siekmeier R.
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
    [Abstract] [Full Text] [Related]

  • 4. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
    Romeo G, Salanitri G, Catania G.
    Drugs Exp Clin Res; 1988 Nov; 14(6):423-7. PubMed ID: 2850903
    [Abstract] [Full Text] [Related]

  • 5. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V, Omri A, Kruithof EK, Hauert J, Bachmann F.
    Thromb Haemost; 1988 Jun 16; 59(3):388-91. PubMed ID: 2847348
    [Abstract] [Full Text] [Related]

  • 6. Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.
    Mismetti P, Reynaud J, Tardy-Ponce B, Laporte-Simitsidis S, Scully M, Goodwyn C, Queneau P, Decousus H.
    Thromb Haemost; 1995 Aug 16; 74(2):660-6. PubMed ID: 8585003
    [Abstract] [Full Text] [Related]

  • 7. Suppression of intimal hyperplasia with low molecular weight heparin in a sheep model.
    Ao PY, Hawthorne WJ, Coombs R, Fletcher JP.
    Int Angiol; 1999 Jun 16; 18(2):131-9. PubMed ID: 10424369
    [Abstract] [Full Text] [Related]

  • 8. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M, Weltermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1995 Mar 16; 73(3):439-43. PubMed ID: 7667826
    [Abstract] [Full Text] [Related]

  • 9. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J, Giese C, Dempfle CE, Stehle G, Heene DL.
    Thromb Haemost; 1989 Jun 30; 61(3):357-62. PubMed ID: 2552604
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
    Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H.
    J Clin Pharmacol; 2008 Oct 30; 48(10):1189-96. PubMed ID: 18716314
    [Abstract] [Full Text] [Related]

  • 11. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs.
    Mischke R, Grebe S, Jacobs C, Kietzmann M.
    Am J Vet Res; 2001 Apr 30; 62(4):595-8. PubMed ID: 11327470
    [Abstract] [Full Text] [Related]

  • 12. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, Aiach M.
    Br J Clin Pharmacol; 1995 Dec 30; 40(6):577-84. PubMed ID: 8703665
    [Abstract] [Full Text] [Related]

  • 13. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L, Arnout J, Vanhove P, Dol F, Lormeau JC, Herbert JM, Collen D, Van de Werf F.
    Coron Artery Dis; 1995 Mar 30; 6(3):257-63. PubMed ID: 7788040
    [Abstract] [Full Text] [Related]

  • 14. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
    Mismetti P, Laporte-Simitsidis S, Navarro C, Sié P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B.
    Thromb Haemost; 1998 Jun 30; 79(6):1162-5. PubMed ID: 9657442
    [Abstract] [Full Text] [Related]

  • 15. Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin.
    Holst J, Lindblad B, Matthíasson SE, Stjernquist U, Ezban M, Ostergaard PB, Hedner U.
    Thromb Haemost; 1996 Apr 30; 75(4):585-9. PubMed ID: 8743183
    [Abstract] [Full Text] [Related]

  • 16. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G, Heiden M, Köhler M.
    Arzneimittelforschung; 1993 May 30; 43(5):542-7. PubMed ID: 8392345
    [Abstract] [Full Text] [Related]

  • 17. Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients.
    Palareti G, Legnani C, Bianchini B, Guazzaloca G, Maccaferri M, Marabini A, De Iaco P, Marcozzi S, Mancini L, Orlandi C.
    Int Angiol; 1989 May 30; 8(1):47-52. PubMed ID: 2768958
    [Abstract] [Full Text] [Related]

  • 18. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O, Lybeck E, Strandberg K, Tynngård N, Schött U.
    PLoS One; 2015 May 30; 10(1):e0116835. PubMed ID: 25625201
    [Abstract] [Full Text] [Related]

  • 19. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK, Thomson AR, Moriarty HT.
    Pathology; 2001 Aug 30; 33(3):347-52. PubMed ID: 11523938
    [Abstract] [Full Text] [Related]

  • 20. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 30; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.